Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.

Trial Profile

QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2018

At a glance

  • Drugs YE-NEO-001 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Acronyms QUILT-2.025 NANT
  • Sponsors NantBioScience
  • Most Recent Events

    • 15 Aug 2018 Status changed from not yet recruiting to recruiting.
    • 20 Jun 2018 New trial record
    • 03 Jun 2018 According to a NANT media release, the US FDA has authorized this phase 1 study for an investigational Neoepitope Yeast Vaccine, YE-NEO-001, in patients previously treated for cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top